Ironwood and Forest to Present Additional Phase 2b Data for Novel Gastrointestinal Agent Linaclotide

- Data to be presented at Digestive Disease Week 2009 - CAMBRIDGE, Mass. and NEW YORK, May 12, 2009 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX ) today announced they will be reporting additional clinical data from their Phase 2b studies...

Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation

...nic constipation and shortly, we expect to begin Phase III trials for the additional indication of constipation predominant irritable bowel syndrome. linaclotide is a promising novel compound that may offer a much needed therapy for this very large and underserved patient population. Later this year we anticip...

Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80

... clinical results for three other late-stage pipeline products; aclidinium, linaclotide and cariprazine. Regarding aclidinium, we reported positive Phase III ACCLA...anuary 2009, following the initiation of the Phase III clinical program for linaclotide for the treatment of chronic constipation in September. Lastly, we reported...

Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment

...obstructive pulmonary disease; ceftaroline for serious hospital infections; linaclotide for the treatment of chronic constipation and constipation predominant irri...o submit to the FDA for review and reported positive Phase II-B results for linaclotide in the treatment of both chronic constipation and irritable bowel syndrome....

Linaclotide in Medical Technology

Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

-- Data Presented Today at DDW Demonstrate Linaclotide Provided Early Onset of Abdominal Pain Relief and Improved Bowel Habits -- CAMBRIDGE, Mass. and NEW YORK, May 31, 2009 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX ) today announced r...

Ironwood Announces Linaclotide European Licensing Agreement with Almirall

- Ironwood Will Receive Up To $55 Million in Near Term Payments - CAMBRIDGE, Mass., May 4 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc. today announced that the company has entered into an out-licensing agreement with Laboratorios Almirall, S.A. for European rights to develop and commerciali...

Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

- Data Presented Today at ACG Annual Scientific Meeting - ORLANDO, Fla., Oct. 7 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals, Inc. (formerly Microbia, Inc.) and Forest Laboratories, Inc. (NYSE: FRX ) today announced the presentation of results from a Phase 2b study assessing lina...

Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3

CAMBRIDGE, Mass., Oct. 1 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc. today announced it has raised $50 million in a private equity financing. This capital will be utilized to support the ongoing Phase 3 development program evaluating linaclotide for the treatment of irritable bowel syndrome...

Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference

- Comprehensive Phase 3 Clinical Program Initiated - CAMBRIDGE, Mass. and NEW YORK, Sept. 23 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals (formerly Microbia) and Forest Laboratories, Inc. (NYSE: FRX ) today announced they will present results of a Phase 2b study investigating ...

Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results

- Data being presented today at Digestive Disease Week - CAMBRIDGE, Mass. and NEW YORK, May 20 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals, Inc. (formerly Microbia, Inc.) and Forest Laboratories, Inc. (NYSE: FRX ) today announced the presentation of data from a Phase 2b randomi...

Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies

- Chronic constipation and IBS-C studies each meet primary endpoint - CAMBRIDGE, MASS. and NEW YORK, March 4 /PRNewswire-FirstCall/ -- Microbia, Inc. and Forest Laboratories, Inc. (NYSE: FRX ) today announced positive top-line results from two Phase 2b randomized, double-blind, placebo-contr...

Microbia Announces Positive Phase 2 Results for Its Investigational Compound Linaclotide

- Data being presented today at Digestive Disease Week - CAMBRIDGE, Mass., May 21, 2007 /PRNewswire/ -- Microbia today announced the presentation of data from a Phase 2 study in which linaclotide accelerated colonic transit and improved bowel function in patients with constipation- predominant irr...

Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain

...ar cGMP levels by stimulating guanylate cyclase C. linaclotide is currently being evaluated in a comprehensive Ph...rders. In a Phase 2b study in patients with IBS-C, linaclotide reduced abdominal pain and improved bowel habits. ... pain observed in patients with IBS-C treated with linaclotide in our Phase 2b studies," said Mark Currie, Ph.D.,...

Linaclotide in Biological Technology

Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration

CAMBRIDGE, Mass. and NEW YORK, Sept. 17 /PRNewswire-FirstCall/ -- Microbia, Inc. and Forest Laboratories, Inc. (NYSE: FRX ), today announced that they have entered into a 50/50 partnership in the United States to co-develop and co-market Microbia's first-in-class compound linaclotide. Linaclo...